The regulation of catalase activity by PPAR γ is affected by α-synuclein

Annals of Clinical and Translational Neurology

Volumn 1, Issue 3, 2014, Pages 145-159

  Yakunin, Eugenia ^a   Kisos, Haya ^a   Kulik, Willem ^b   Grigoletto, Jessica ^a   Wanders, Ronald J A ^b   Sharon, Ronit ^a  

^a HEBREW UNIVERSITY OF JERUSALEM   (Israel)

^b UNIVERSITY OF AMSTERDAM   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ALITRETINOIN; ALPHA SYNUCLEIN; CATALASE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; RETINOID X RECEPTOR; TROGLITAZONE;

ALZHEIMER DISEASE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BIOCHEMICAL ANALYSIS; CONFOCAL MICROSCOPY; CONTROLLED STUDY; DISEASE COURSE; DOWN REGULATION; ENZYMATIC ASSAY; ENZYME ACTIVITY; FLUORESCENCE ACTIVATED CELL SORTING; GENE EXPRESSION REGULATION; GENETIC TRANSCRIPTION; IMMUNOHISTOCHEMISTRY; MOUSE; NONHUMAN; OXIDATION; PEROXISOME; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; WESTERN BLOTTING;

EID: 85015211785     PISSN: None     EISSN: 23289503     Source Type: Journal    
DOI: 10.1002/acn3.38     Document Type: Article

References (71)

1. Dexter DT, Carter CJ, Wells FR, et al. Basal lipid peroxidation in substantia nigra is increased in Parkinson's disease. J Neurochem 1989;52:381–389.
2. Alam ZI, Jenner A, Daniel SE, et al. Oxidative DNA damage in the parkinsonian brain: an apparent selective increase in 8-hydroxyguanine levels in substantia nigra. J Neurochem 1997;69:1196–1203.
3. Nakabeppu Y, Tsuchimoto D, Yamaguchi H, Sakumi K. Oxidative damage in nucleic acids and Parkinson's disease. J Neurosci Res 2007;85:919–934.
4. Ambani LM, Van Woert MH, Murphy S. Brain peroxidase and catalase in Parkinson disease. Arch Neurol 1975;32:114–118.
5. Kish SJ, Morito C, Hornykiewicz O. Glutathione peroxidase activity in Parkinson's disease brain. Neurosci Lett 1985;58:343–346.
6. Zhou C, Huang Y, Przedborski S. Oxidative stress in Parkinson's disease: a mechanism of pathogenic and therapeutic significance. Ann N Y Acad Sci 2008;1147:93–104.
7. Vekrellis K, Xilouri M, Emmanouilidou E, et al. Pathological roles of alpha-synuclein in neurological disorders. Lancet Neurol 2011;10:1015–1025.
8. Goedert M, Spillantini MG, Del Tredici K, Braak H. 100 years of Lewy pathology. Nat Rev Neurol 2013;9:13–24.
9. Baba M, Nakajo S, Tu PH, et al. Aggregation of alpha-synuclein in Lewy bodies of sporadic Parkinson's disease and dementia with Lewy bodies. Am J Pathol 1998;152:879–884.
10. Jellinger KA. Neuropathology of sporadic Parkinson's disease: evaluation and changes of concepts. Mov Disord 2012;27:8–30.
11. Duda JE, Lee VM, Trojanowski JQ. Neuropathology of synuclein aggregates. J Neurosci Res 2000;61:121–127.
12. Ruiperez V, Darios F, Davletov B. Alpha-synuclein, lipids and Parkinson's disease. Prog Lipid Res 2010;49:420–428.
13. Yakunin E, Loeb V, Kisos H, et al. Alpha-synuclein neuropathology is controlled by nuclear hormone receptors and enhanced by docosahexaenoic acid in a mouse model for Parkinson's disease. Brain Pathol 2012;22:280–294.
14. Girnun GD, Domann FE, Moore SA, Robbins ME. Identification of a functional peroxisome proliferator-activated receptor response element in the rat catalase promoter. Mol Endocrinol 2002;16:2793–2801.
15. Gray E, Ginty M, Kemp K, et al. The PPAR-gamma agonist pioglitazone protects cortical neurons from inflammatory mediators via improvement in peroxisomal function. J Neuroinflammation 2012;9:63.
16. Giasson BI, Duda JE, Quinn SM, et al. Neuronal alpha-synucleinopathy with severe movement disorder in mice expressing A53T human alpha-synuclein. Neuron 2002;34:521–533.
17. Jankowsky JL, Fadale DJ, Anderson J, et al. Mutant presenilins specifically elevate the levels of the 42 residue beta-amyloid peptide in vivo: evidence for augmentation of a 42-specific gamma secretase. Hum Mol Genet 2004;13:159–170.
18. Choi HK, Won LA, Kontur PJ, et al. Immortalization of embryonic mesencephalic dopaminergic neurons by somatic cell fusion. Brain Res 1991;552:67–76.
19. Assayag K, Yakunin E, Loeb V, et al. Polyunsaturated fatty acids induce {alpha}-synuclein-related pathogenic changes in neuronal cells. Am J Pathol 2007;171:2000–2011.
20. Kovacs WJ, Faust PL, Keller GA, Krisans SK. Purification of brain peroxisomes and localization of 3-hydroxy-3-methylglutaryl coenzyme A reductase. Eur J Biochem 2001;268:4850–4859.
21. Bradford MM. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 1976;72:248–254.
22. Loeb V, Yakunin E, Saada A, Sharon R. The transgenic over expression of {alpha}-synuclein and not its related pathology, associates with complex I inhibition. J Biol Chem 2010;285:7334–7343.
23. Ahlemeyer B, Neubert I, Kovacs WJ, Baumgart-Vogt E. Differential expression of peroxisomal matrix and membrane proteins during postnatal development of mouse brain. J Comp Neurol 2007;505:1–17.
24. Jones P, Suggett A. The catalse-hydrogen peroxide system. Kinetics of catalatic action at high substrate concentrations. Biochem J 1968;110:617–620.
25. Levine RL, Williams JA, Stadtman ER, Shacter E. Carbonyl assays for determination of oxidatively modified proteins. Methods Enzymol 1994;233:346–357.
26. Chevion M, Berenshtein E, Stadtman ER. Human studies related to protein oxidation: protein carbonyl content as a marker of damage. Free Radic Res 2000;33(Suppl):S99–S108.
27. Dacremont G, Vincent G. Assay of plasmalogens and polyunsaturated fatty acids (PUFA) in erythrocytes and fibroblasts. J Inherit Metab Dis 1995;18(Suppl. 1):84–89.
28. Varanasi U, Chu R, Huang Q, et al. Identification of a peroxisome proliferator-responsive element upstream of the human peroxisomal fatty acyl coenzyme A oxidase gene. J Biol Chem 1996;271:2147–2155.
29. Marcus SL, Miyata KS, Zhang B, et al. Diverse peroxisome proliferator-activated receptors bind to the peroxisome proliferator-responsive elements of the rat hydratase/dehydrogenase and fatty acyl-CoA oxidase genes but differentially induce expression. Proc Natl Acad Sci USA 1993;90:5723–5727.
30. Gray E, Ginty M, Kemp K, et al. Peroxisome proliferator-activated receptor-alpha agonists protect cortical neurons from inflammatory mediators and improve peroxisomal function. Eur J Neurosci 2011;33:1421–1432.
31. Brocard C, Lametschwandtner G, Koudelka R, Hartig A. Pex14p is a member of the protein linkage map of Pex5p. EMBO J 1997;16:5491–5500.
32. Jankowsky JL, Xu G, Fromholt D, et al. Environmental enrichment exacerbates amyloid plaque formation in a transgenic mouse model of Alzheimer disease. J Neuropathol Exp Neurol 2003;62:1220–1227.
33. Sharon R, Bar-Joseph I, Frosch MP, et al. The formation of highly soluble oligomers of alpha-synuclein is regulated by fatty acids and enhanced in Parkinson's disease. Neuron 2003;37:583–595.
34. Sharon R, Bar-Joseph I, Mirick GE, et al. Altered fatty acid composition of dopaminergic neurons expressing alpha-synuclein and human brains with alpha-synucleinopathies. J Biol Chem 2003;278:49874–49881.
35. Galvin JE, Lee VM, Trojanowski JQ. Synucleinopathies: clinical and pathological implications. Arch Neurol 2001;58:186–190.
36. De Franceschi G, Frare E, Pivato M, et al. Structural and morphological characterization of aggregated species of alpha-synuclein induced by docosahexaenoic acid. J Biol Chem 2011;286:22262–22274.
37. Riedel M, Goldbaum O, Wille M, Richter-Landsberg C. Membrane lipid modification by docosahexaenoic acid (DHA) promotes the formation of alpha-synuclein inclusion bodies immunopositive for SUMO-1 in oligodendroglial cells after oxidative stress. J Mol Neurosci 2011;43:290–302.
38. Gao HM, Kotzbauer PT, Uryu K, et al. Neuroinflammation and oxidation/nitration of alpha-synuclein linked to dopaminergic neurodegeneration. J Neurosci 2008;28:7687–7698.
39. Zheng K, Heydari B, Simon DK. A common NURR1 polymorphism associated with Parkinson disease and diffuse Lewy body disease. Arch Neurol 2003;60:722–725.
40. Xu PY, Liang R, Jankovic J, et al. Association of homozygous 7048G7049 variant in the intron six of Nurr1 gene with Parkinson's disease. Neurology 2002;58:881–884.
41. Bonekamp NA, Volkl A, Fahimi HD, Schrader M. Reactive oxygen species and peroxisomes: struggling for balance. Biofactors 2009;35:346–355.
42. Rhee SG, Kang SW, Jeong W, et al. Intracellular messenger function of hydrogen peroxide and its regulation by peroxiredoxins. Curr Opin Cell Biol 2005;17:183–189.
43. Beckman KB, Ames BN. The free radical theory of aging matures. Physiol Rev 1998;78:547–581.
44. Kregel KC, Zhang HJ. An integrated view of oxidative stress in aging: basic mechanisms, functional effects, and pathological considerations. Am J Physiol Regul Integr Comp Physiol 2007;292:R18–R36.
45. Uchida K. 4-Hydroxy-2-nonenal: a product and mediator of oxidative stress. Prog Lipid Res 2003;42:318–343.
46. Schaur RJ. Basic aspects of the biochemical reactivity of 4-hydroxynonenal. Mol Aspects Med 2003;24:149–159.
47. Harman D. Aging: a theory based on free radical and radiation chemistry. J Gerontol 1956;11:298–300.
48. Lee SJ, Hwang AB, Kenyon C. Inhibition of respiration extends C. elegans life span via reactive oxygen species that increase HIF-1 activity. Curr Biol 2010;20:2131–2136.
49. Durieux J, Wolff S, Dillin A. The cell-non-autonomous nature of electron transport chain-mediated longevity. Cell 2011;144:79–91.
50. Kawada Y, Khan M, Sharma AK, et al. Inhibition of peroxisomal functions due to oxidative imbalance induced by mistargeting of catalase to cytoplasm is restored by vitamin E treatment in skin fibroblasts from Zellweger syndrome-like patients. Mol Genet Metab 2004;83:297–305.
51. Schriner SE, Linford NJ, Martin GM, et al. Extension of murine life span by overexpression of catalase targeted to mitochondria. Science 2005;308:1909–1911.
52. Schapira AH. Targeting mitochondria for neuroprotection in Parkinson's disease. Antioxid Redox Signal 2012;16:965–973.
53. Boveris A, Oshino N, Chance B. The cellular production of hydrogen peroxide. Biochem J 1972;128:617–630.
54. Giasson BI, Duda JE, Murray IV, et al. Oxidative damage linked to neurodegeneration by selective alpha-synuclein nitration in synucleinopathy lesions. Science 2000;290:985–989.
55. Duda JE, Giasson BI, Chen Q, et al. Widespread nitration of pathological inclusions in neurodegenerative synucleinopathies. Am J Pathol 2000;157:1439–1445.
56. Souza JM, Giasson BI, Chen Q, et al. Dityrosine cross-linking promotes formation of stable alpha -synuclein polymers. Implication of nitrative and oxidative stress in the pathogenesis of neurodegenerative synucleinopathies. J Biol Chem 2000;275:18344–18349.
57. Takahashi T, Yamashita H, Nakamura T, et al. Tyrosine 125 of alpha-synuclein plays a critical role for dimerization following nitrative stress. Brain Res 2002;938:73–80.
58. Radi R. Nitric oxide, oxidants, and protein tyrosine nitration. Proc Natl Acad Sci USA 2004;101:4003–4008.
59. Rappley I, Myers DS, Milne SB, et al. Lipidomic profiling in mouse brain reveals differences between ages and genders, with smaller changes associated with alpha-synuclein genotype. J Neurochem 2009;111:15–25.
60. Golovko MY, Rosenberger TA, Feddersen S, et al. Alpha-synuclein gene ablation increases docosahexaenoic acid incorporation and turnover in brain phospholipids. J Neurochem 2007;101:201–211.
61. Golovko MY, Faergeman NJ, Cole NB, et al. Alpha-synuclein gene deletion decreases brain palmitate uptake and alters the palmitate metabolism in the absence of alpha-synuclein palmitate binding. Biochemistry 2005;44:8251–8259.
62. Ellis CE, Murphy EJ, Mitchell DC, et al. Mitochondrial lipid abnormality and electron transport chain impairment in mice lacking alpha-synuclein. Mol Cell Biol 2005;25:10190–10201.
63. Zheng B, Liao Z, Locascio JJ, et al. PGC-1alpha, a potential therapeutic target for early intervention in Parkinson's disease. Sci Transl Med 2010;2:52ra73.
64. Siddiqui A, Chinta SJ, Mallajosyula JK, et al. Selective binding of nuclear alpha-synuclein to the PGC1alpha promoter under conditions of oxidative stress may contribute to losses in mitochondrial function: implications for Parkinson's disease. Free Radic Biol Med 2012;53:993–1003.
65. Brites P, Waterham HR, Wanders RJ. Functions and biosynthesis of plasmalogens in health and disease. Biochim Biophys Acta 2004;1636:219–231.
66. Wanders RJ, Waterham HR. Biochemistry of mammalian peroxisomes revisited. Annu Rev Biochem 2006;75:295–332.
67. Hoefler S, Hoefler G, Moser AB, et al. Prenatal diagnosis of rhizomelic chondrodysplasia punctata. Prenat Diagn 1988;8:571–576.
68. Ofman R, Hettema EH, Hogenhout EM, et al. Acyl-CoA: dihydroxyacetonephosphate acyltransferase: cloning of the human cDNA and resolution of the molecular basis in rhizomelic chondrodysplasia punctata type 2. Hum Mol Genet 1998;7:847–853.
69. Brookhyser KM, Lipson MH, Moser AB, et al. Prenatal diagnosis of rhizomelic chondrodysplasia punctata due to isolated alkyldihydroacetonephosphate acyltransferase synthase deficiency. Prenat Diagn 1999;19:383–385.
70. Snyder F. Metabolism of platelet activating factor and related ether lipids: enzymatic pathways, subcellular sites, regulation, and membrane processing. Prog Clin Biol Res 1988;282:57–72.
71. Yakunin E, Moser A, Loeb V, et al. Alpha-synuclein abnormalities in mouse models of peroxisome biogenesis disorders. J Neurosci Res 2010;88:866–876.